Corbus Pharmaceuticals Holdings, Inc. (CRBP): Capital Expenditures
$7.0K
Year ended 2025-12-31
$19.0K
Trailing 12 months to 2026-06-30
-19.6%
3-year compound annual growth
-57.1%
5-year compound annual growth
-24.4%
10-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $7.0K | n/a | 2026-03-09, From 2025-01-01 |
| 2024-12-31 | $0 | n/a | 2026-03-09, From 2024-01-01 |
| 2023-12-31 | $0 | -100.0% | 2024-03-12, From 2023-01-01 |
| 2022-12-31 | $13.4K | -75.2% | 2024-03-12, From 2022-01-01 |
| 2021-12-31 | $54.2K | -88.8% | 2023-03-07, From 2021-01-01 |
| 2020-12-31 | $484.5K | -82.3% | 2022-03-08, From 2020-01-01 |
| 2019-12-31 | $2.74M | +19.2% | 2021-03-15, From 2019-01-01 |
| 2018-12-31 | $2.30M | +225.2% | 2020-03-16, From 2018-01-01 |
| 2017-12-31 | $707.4K | +100.4% | 2019-03-12, From 2017-01-01 |
| 2016-12-31 | $353.0K | +209.6% | 2018-03-12, From 2016-01-01 |
| 2015-12-31 | $114.0K | +76.9% | 2018-03-12, From 2015-01-01 |
| 2014-12-31 | $64.4K | n/a | 2016-03-28, From 2014-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | 2025-12-31 | $7.0K | n/a |
| Climb Bio, Inc. (CLYM) | 2025-12-31 | $186.0K | n/a |
| Gyre Therapeutics, Inc. (GYRE) | 2025-12-31 | $1.19M | -48.6% |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | $79.0K | n/a |
| Apimeds Pharmaceuticals US, Inc. (APUS) | 2025-12-31 | $57.3K | n/a |
| PepGen Inc. (PEPG) | 2025-12-31 | $264.0K | -46.9% |
| Transcode Therapeutics, Inc. (RNAZ) | 2025-12-31 | $6.7K | -69.4% |
| Aclaris Therapeutics, Inc. (ACRS) | 2025-12-31 | $111.0K | -8.3% |
| Aquestive Therapeutics, Inc. (AQST) | 2025-12-31 | $562.0K | +253.5% |
Compare CRBP, CLYM, GYRE, GOSS side by side · Screen every company in Pharmaceutical Preparations ↗